Summer Sale
50% off Premium Yearly
NYSE:DOCS
Doximity (DOCS)
Financials 
Technical Analysis 
Aug 23, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Doximity (DOCS-N) has garnered mixed reviews from experts, particularly highlighting concerns regarding its current valuation. Several analysts believe that the stock is still trading at a high price despite recent performance issues, notably a disappointing last quarter. This raises questions about its growth prospects and sustainability at present levels. There is a consensus that the stock may not be an attractive buy at this time, as the market sentiment aligns with caution rather than optimism. Overall, the outlook for Doximity seems uncertain, with calls for a reassessment of its financial fundamentals and market position.
DOCS has erased earlier gains from its last earnings report, amid the market drawdown, but it continues to be on a long-term uptrend, and forward sales and earnings estimates are strong. Analyst estimates have been trending higher in the past year, margins have been expanding, and it generates decent cash flows. It has a good balance sheet, but it is not cheap at 38X forward earnings. For a long-term investor, we would be comfortable holding here given its fundamental strength.
Unlock Premium - Try 5i Free
Up 38% since IPO in fall 2021. Shares got killed last year during inflation and rate hikes. Has since rebounded. It's been a round trip. Their last report was solid, but guidance was ugly, given a delay in their new telemedicine product given regulatory interference. But they've beaten every quarter. Pricey at 47x PE 2023 but are profitable.
- «
- ‹
- 1
- ›
- »
Popular Articles
Most Recent Experts
Doximity (DOCS) Frequently Asked Questions
What is Doximity stock symbol?
Doximity is a American stock, trading under the symbol DOCS (previously DOCS-N on Stockchase) on the New York Stock Exchange (DOCS). It is usually referred to as NYSE:DOCS or DOCS
Is Doximity a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on DOCS (previously DOCS-N on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Doximity.
Is Doximity a good investment or a top pick?
Doximity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Doximity.
Why is Doximity stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Doximity.
Is Doximity worth watching?
Doximity is covered by Stockchase experts and is worth watching.
What is Doximity stock price?
On 2026-08-21, Doximity (DOCS) stock closed at a price of $25.33.
Is still too expensive. Their last quarter wasn't that good.